50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.35 (+-0.01%)
AAPL   151.70 (+0.62%)
MSFT   236.41 (-0.44%)
META   134.38 (-1.46%)
GOOGL   97.35 (-0.84%)
AMZN   114.36 (-0.69%)
TSLA   283.18 (+2.60%)
NVDA   124.11 (+1.50%)
NIO   17.21 (-2.33%)
BABA   78.06 (-1.08%)
AMD   67.20 (+1.36%)
T   15.72 (+0.32%)
MU   50.53 (+3.38%)
CGC   2.87 (+4.74%)
F   11.92 (-0.58%)
GE   64.35 (+0.00%)
DIS   95.85 (-2.31%)
AMC   7.46 (+9.22%)
PYPL   85.76 (+1.78%)
PFE   44.12 (+0.66%)
NFLX   224.54 (+0.21%)
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.35 (+-0.01%)
AAPL   151.70 (+0.62%)
MSFT   236.41 (-0.44%)
META   134.38 (-1.46%)
GOOGL   97.35 (-0.84%)
AMZN   114.36 (-0.69%)
TSLA   283.18 (+2.60%)
NVDA   124.11 (+1.50%)
NIO   17.21 (-2.33%)
BABA   78.06 (-1.08%)
AMD   67.20 (+1.36%)
T   15.72 (+0.32%)
MU   50.53 (+3.38%)
CGC   2.87 (+4.74%)
F   11.92 (-0.58%)
GE   64.35 (+0.00%)
DIS   95.85 (-2.31%)
AMC   7.46 (+9.22%)
PYPL   85.76 (+1.78%)
PFE   44.12 (+0.66%)
NFLX   224.54 (+0.21%)
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.35 (+-0.01%)
AAPL   151.70 (+0.62%)
MSFT   236.41 (-0.44%)
META   134.38 (-1.46%)
GOOGL   97.35 (-0.84%)
AMZN   114.36 (-0.69%)
TSLA   283.18 (+2.60%)
NVDA   124.11 (+1.50%)
NIO   17.21 (-2.33%)
BABA   78.06 (-1.08%)
AMD   67.20 (+1.36%)
T   15.72 (+0.32%)
MU   50.53 (+3.38%)
CGC   2.87 (+4.74%)
F   11.92 (-0.58%)
GE   64.35 (+0.00%)
DIS   95.85 (-2.31%)
AMC   7.46 (+9.22%)
PYPL   85.76 (+1.78%)
PFE   44.12 (+0.66%)
NFLX   224.54 (+0.21%)
S&P 500   3,647.29 (-0.21%)
DOW   29,134.99 (-0.43%)
QQQ   274.35 (+-0.01%)
AAPL   151.70 (+0.62%)
MSFT   236.41 (-0.44%)
META   134.38 (-1.46%)
GOOGL   97.35 (-0.84%)
AMZN   114.36 (-0.69%)
TSLA   283.18 (+2.60%)
NVDA   124.11 (+1.50%)
NIO   17.21 (-2.33%)
BABA   78.06 (-1.08%)
AMD   67.20 (+1.36%)
T   15.72 (+0.32%)
MU   50.53 (+3.38%)
CGC   2.87 (+4.74%)
F   11.92 (-0.58%)
GE   64.35 (+0.00%)
DIS   95.85 (-2.31%)
AMC   7.46 (+9.22%)
PYPL   85.76 (+1.78%)
PFE   44.12 (+0.66%)
NFLX   224.54 (+0.21%)
NASDAQ:SVRA

Savara - SVRA Stock Forecast, Price & News

$1.45
+0.09 (+6.62%)
(As of 09/27/2022 03:59 PM ET)
Add
Compare
Today's Range
$1.36
$1.45
50-Day Range
$1.36
$1.83
52-Week Range
$1.02
$1.91
Volume
5,545 shs
Average Volume
94,189 shs
Market Capitalization
$165.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Savara MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.92mentions of Savara in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$96,212 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.26) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

881st out of 1,071 stocks

Pharmaceutical Preparations Industry

421st out of 531 stocks

SVRA stock logo

About Savara (NASDAQ:SVRA) Stock

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Receive SVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter.

SVRA Stock News Headlines

Savara's chief medical officer resigns - Seeking Alpha
Savara Announces Resignation of Chief Medical Officer
Savara, Inc. (NASDAQ: SVRA)
Recap: Savara Q2 Earnings - Benzinga
See More Headlines
Receive SVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter.

SVRA Company Calendar

Last Earnings
8/11/2022
Today
9/27/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SVRA
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-43,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$260,000.00
Book Value
$1.27 per share

Miscellaneous

Free Float
109,972,000
Market Cap
$165.36 million
Optionable
Optionable
Beta
0.93

Key Executives

  • Robert N. Neville (Age 51)
    Chairman of the Board, Chief Executive Officer
  • Taneli Jouhikainen (Age 51)
    President, Chief Operating Officer
  • David L. Lowrance (Age 50)
    Chief Financial Officer
  • Nevan C. Elam (Age 49)
    Independent Director
  • Richard J. Hawkins (Age 68)
    Independent Director
  • Joseph S. McCracken Ph.D. (Age 64)
    Independent Director
  • Matthew Pauls J.D.Matthew Pauls J.D. (Age 46)
    Independent Director
  • Yuri Pikover (Age 56)
    Independent Director













SVRA Stock - Frequently Asked Questions

How have SVRA shares performed in 2022?

Savara's stock was trading at $1.24 on January 1st, 2022. Since then, SVRA stock has increased by 10.5% and is now trading at $1.37.
View the best growth stocks for 2022 here
.

When is Savara's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our SVRA earnings forecast
.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) released its quarterly earnings results on Thursday, August, 11th. The company reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06).

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CEL-SCI (CVM), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

Who are Savara's major shareholders?

Savara's stock is owned by many different institutional and retail investors. Top institutional investors include Sio Capital Management LLC (0.75%), Franklin Resources Inc. (0.16%), Millennium Management LLC (0.14%), Connor Clark & Lunn Investment Management Ltd. (0.13%), Renaissance Technologies LLC (0.05%) and Goldman Sachs Group Inc. (0.05%). Insiders that own company stock include Badrul A Chowdhury, David A Ramsay, David L Lowrance, Joseph S Mccracken and Matthew Pauls.
View institutional ownership trends
.

How do I buy shares of Savara?

Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $1.37.

How much money does Savara make?

Savara (NASDAQ:SVRA) has a market capitalization of $156.23 million and generates $260,000.00 in revenue each year. The company earns $-43,010,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The official website for the company is www.savarapharma.com. The company can be reached via phone at 512-614-1848, via email at ir@savarapharma.com, or via fax at 858-552-0876.

This page (NASDAQ:SVRA) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.